ORIGINAL ARTICLE

Disparities in oxygen saturation and hypoxic burden levels in obstructive sleep apnoea patient’s response to oral appliance treatment

Ji Woon Park1,2,3 | Fernanda R. Almeida1

1Department of Oral Health Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC, Canada
2Department of Oral Medicine and Oral Diagnosis, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Korea
3Department of Oral Medicine, Seoul National University Dental Hospital, Seoul, Korea

Correspondence
Fernanda R. Almeida, Department of Oral Health Sciences, Faculty of Dentistry, University of British Columbia, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
Email: falmeida@dentistry.ubc.ca

Abstract
Background: Oxygen saturation indices show a strong correlation with long-term health outcomes. Nonetheless, evidence on the relationship between reduction in respiratory events and increase in oxygenation levels following oral appliance (OA) treatment is scarce.

Objectives: To verify the relationship between reduction in the apnoea-hypopnoea index (AHI) and oxygen saturation levels following OA treatment, we have conducted an evaluation of polysomnography (PSG) and clinical parameters associated with the improvement of oxygen desaturation.

Methods: OSA patients (n = 48) who received an OA and had pre- and post-treatment PSG were classified into three responder groups according to the change in AHI and min O₂ post-treatment: responder_AHInOnly (decrease in AHI of ≥50% but increase in min O₂ level of <4% or decrease); responder_MinO₂inOnly (increase in min O₂ level of ≥4% but decrease in AHI <50% or increase) and responder_Congruous (decrease in AHI of ≥50% and increase in min O₂ level of ≥4%). Various demographic and PSG variables were statistically compared among groups.

Results: There were 26 (54.17%) responder_AHInOnly, 9 (18.75%) responder_MinO₂inOnly and 13 (27.08%) responder_Congruous. Pre-treatment min O₂ was significantly lower in responder_MinO₂inOnly. A higher pre-treatment min O₂ showed a significant correlation with a smaller amount of change in mean O₂ (r = −.486) and min O₂ (r = −.764) with treatment. Pre-treatment min O₂ showed the strongest ability to predict those who would show a ≥4% min O₂ increase following treatment.

Conclusion: Certain patients do not show sufficient decrease in hypoxaemia in spite of the improvement in AHI. Pre-treatment min O₂ should be considered in OA treatment planning regarding its close relation to improvements in oxygenation levels with treatment.

KEYWORDS
hypoxic burden, mandibular advancement device, obstructive sleep apnoea, oxygen saturation, responder, sleep disordered breathing

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Journal of Oral Rehabilitation published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Obstructive sleep apnoea (OSA) is caused by repeated obstruction of the upper airway that is followed by partial or complete interruption of airflow during sleep. OSA affects 3%–20% of the general population with prevalence showing a significant increase along with its socioeconomic burden. Untreated OSA is associated with long-term adverse health outcomes including cardiovascular disease, endocrine disorders and also motor vehicle accidents that may cause fatality. Appropriate therapy can improve symptoms and reduce associated sequelae to some extent. Continuous positive airway pressure (CPAP) is considered the first-line therapy for OSA; however, many patients experience difficulty in its usage and adherence remains generally low with 30% of the initially compliant patients failing to use CPAP at 5 years. Based on such observations, oral appliances (OA) are recommended for OSA management.

Growing evidence confirmed that even severe OSA can be successfully treated with OAs that protrude the mandible to maintain upper airway patency and decrease its collapsibility through various mechanisms. OA treatment for OSA has shown to reduce the number of respiratory events and increase oxygen saturation levels. The success rate for OA treatment is 50%–75% with >50% reduction in pre-treatment apnoea-hypopnoea index (AHI) as the criteria is 50%–75% according to various studies. However, studies defining treatment success based on the improvement in oxygen saturation levels are scarce and this is also true in evaluating the efficacy of other OSA treatments including CPAP. Intermittent hypoxia and oxygen desaturation, the main hallmarks of OSA, are known to cause alterations in gene expression and cell metabolism, which are directly related to the adverse systemic sequelae and increased mortality of OSA. Although AHI is the most commonly used index for evaluating OSA, controversies have risen since AHI often fails to show a significant correlation with OSA related complications and comprehensive measurements such as quality of life and treatment response.

Several studies reported that oxygen saturation indices showed a stronger correlation with long-term health outcomes including cardiovascular complications compared to AHI values. Nonetheless, clinical evidence on the relationship between the reduction in respiratory events and increase in oxygenation levels following treatment is limited.

Therefore, the aim of this study was to quantitatively verify the relationship between alterations in AHI and oxygen saturation and hypocapnia burden levels following OA treatment in OSA patients and evaluate polysomnography (PSG) and clinical parameters associated with persistent oxygen desaturation, in spite of improvement in AHI values. Such results should be considered when assessing OSA treatment efficacy and the possibility of adverse health outcomes related to OSA.

2 | MATERIALS AND METHODS

2.1 | Subjects

Patients aged 18 years or older with the complaint of snoring and respiratory problems during sleep, diagnosed to have mild-to-severe OSA (AHI ≥ 5/h), then referred to the Sleep Apnea Dental Clinic at the University of British Columbia (UBC) or to an affiliated private practice for OSA treatment with an OA from January, 2001 to September, 2016 were included in this retrospective study. Those with an initial diagnosis of moderate-to-severe OSA (AHI ≥ 15/h) or mild OSA (AHI ≥ 5/h) with associated symptoms including excessive daytime sleepiness were included only after the patient failed or refused to try CPAP treatment. As inclusion criteria, all subjects underwent clinical and pre- and post-treatment PSG evaluation at the same laboratory for OSA diagnosis and treatment efficacy evaluation.

All patients received an OA at the same university clinic. During clinical examination for OA eligibility, patients with advanced periodontitis, dental caries requiring treatment, active temporomandibular joint disorders and/or less than 6 remaining posterior teeth were excluded. Also, those with uncontrolled psychological, respiratory or cardiovascular disease, pregnancy, acute or chronic systemic inflammatory disease, previous OA or surgical treatment for OSA and lacking comparable PSG data were excluded. Initially, 91 patients diagnosed and treated for OSA were selected for the analysis. Seventeen participants lacked appropriate post-treatment oxygen saturation data. Following the final grouping criteria of treatment responders, we excluded 26 participants that did not show an improvement in both AHI and minimum oxygen saturation levels. The final complete sample was obtained in 48 patients on which final analysis was conducted.

This study was conducted in accordance with the amended Declaration of Helsinki. Approval for the study was obtained from the UBC Clinical Research Ethics Board (H20-02643) and permission was obtained from the dataset owner to use the information for the purposes of the research. This was a retrospective clinical chart review study and acquired data was kept anonymized. The UBC Clinical Research Ethics Board granted exemption from obtaining informed consent.

2.2 | Oral appliance treatment

All patients were fitted with a custom made titratable mandibular advancement OA (Klearway [Great Lakes Orthodontics] and SomnoDent [SomnoMed]). The amount of initial advancement was set at two-thirds of the possible maximum protrusion, and then further advanced by 0.25 mm increments until self-reported resolution of snoring and related symptoms such as daytime sleepiness. Advancements were also stopped when the patient complained of any discomfort due to the appliance. Vertical opening was kept to a minimum of 3–5 mms. Optimal titration was verified by a follow-up sleep study. Recall checks were done every month for the initial 4 months. Patients that were comfortable with their OA after 4 months were scheduled for recall checks at 6 months, 1 year, and 2 years after wearing the appliance.

2.3 | Polysomnographic evaluation of OSA

Attended standardised PSG was performed pre- and post-treatment in the same hospital sleep clinic and scored according to the American
2.5 | Statistical analysis

Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test the normality of data and each following test was selected accordingly. Differences in demographic and clinical parameters and polysomnographic characteristics based on the treatment responder groups were analysed by one-way ANOVA, Kruskal-Wallis one-way ANOVA, and chi-square test. Post-hoc analyses were conducted by Bonferroni correction. Differences in clinical and polysomnographic characteristics before and after OA treatment in each responder response group were analysed by the paired t-test, Wilcoxon Rank-sum test, chi-square test and McNemar’s test. Correlations of pre-treatment polysomnographic and clinical variables and post-treatment oxygen saturation levels and hypoxic burden variables were analysed by Pearson’s correlation coefficient. Multiple linear regression analysis was used to estimate the relationship between pre-treatment polysomnographic and clinical variables as independent variables and post-treatment oxygen saturation levels as dependent variables. Regression analysis was also applied to analyse the magnitude of change in each oxygen saturation and hypoxic burden variable according to a unit change in AHI value in each group. The receiver operating characteristic (ROC) curve and area under the curve (AUC) for being a minimum oxygen saturation responder were analysed to obtain cut-off values of polysomnographic and clinical variables that showed a significant association with post-treatment oxygen saturation levels through regression analyses. The role of AUC as discriminating cut-off values was considered acceptable 0.7–0.8, excellent if values were between 0.8–0.9 or outstanding discrimination if values were >0.9. Calculation for likelihood ratios and predictive values were done with an online programme (https://www.medcalc.org/calc/diagnostic_test.php). All statistical analysis was performed using SPSS 22.0 software programme (IBM). Results were considered statistically significant at a level of $p < .05$.

3 | RESULTS

3.1 | Clinical characteristics and treatment responses of the study group

Initially, 74 patients who were referred for OA therapy for the treatment of OSA completed pre- and post-treatment PSG evaluation at the same institution. As per our study criteria, we excluded from our final analysis 26 (35.14%) patients, as they were non-responders and showed less than 50% reduction in AHI and less than 4% increase in min $O_2$ level following OA treatment. The other 48 (64.86%) patients were responders who showed either a ≥50% reduction in AHI and/or ≥4% increase in min $O_2$. There were no significant differences in age, gender, BMI, AHI, min $O_2$ level, mean apnoea and hypopnoea duration before treatment between responders and non-responders; however, non-responders had a significantly longer mean apnoea duration post-treatment ($p = .034$, data not shown).
Thirty-nine participants (81.25%) showed a ≥50% decrease in AHI and 22 (45.83%) showed a ≥4% increase in min $O_2$ level post-treatment. Sixteen showed resolved AHI (< 5, 33.33%), 17 success (5 ≤ AHI ≤ 10, 35.42%), 11 suboptimal (10 < AHI ≤ 20, 22.92%) and 4 failure (AHI > 20, 8.33%), following treatment. There were 26 (54.17%) in the responder $\text{AHI}_{\text{only}}$ group showing a ≥50% improvement in AHI while the min $O_2$ level improved minimally or did not improve; 9 (18.75%) were in the responder $\text{MinO}_2\text{only}$ group showing a ≥4% improvement in min $O_2$ level while the AHI improved minimally or did not improve, and 13 (27.08%) were responder $\text{Congruous}$ showing an improvement in both variables with a ≥50% decrease in AHI and ≥4% increase in min $O_2$ level. There were no significant differences in confounders such as age, gender, BMI, and cardiovascular conditions both pre- and post-treatment among responder groups. The mean age was lower and BMI was higher both pre- and post-treatment in the responder $\text{AHI}_{\text{only}}$ group, and there were more females compared to the other groups; however, the difference was not statistically significant. As shown in Table 1, there was no significant weight change in any of the groups. The average change in weight was $-2.79 \pm 16.92$ kg.

### 3.2 Magnitude of change in oxygen saturation and hypoxic burden parameters with oral appliance treatment

In the responder $\text{AHI}_{\text{only}}$ group, 1-unit change in AHI corresponded to 0.640 change in ODI. In the responder $\text{MinO}_2\text{only}$ group, 1-unit change in AHI corresponded to 0.810 change in mean $O_2$ and 0.803 change in $T_{95}$. In the responder $\text{Congruous}$ group, 1-unit change in AHI corresponded to 0.701 change in $T_{95}$, 0.935 change in ODI, 0.586 change in mean hypopnoea duration and 0.627 change in longest hypopnoea duration. One-unit change in AHI corresponded to 0.710 change in ODI in the total responder group. The coefficients for all oxygen saturation and hypoxic burden related variables are shown in Table 2.

### 3.3 Polysomnographic characteristics of different responder groups’ oxygen saturation and hypoxic burden levels

For the total sample ($N = 48$), treatment resulted in an increase in mean and min $O_2$ level of 0.12 ± 1.73% and 4.22 ± 7.06%, respectively. There was a decrease in $T_{90}$ of 1.36 ± 6.03% and a decrease in ODI ($N = 24$) of 9.58 ± 10.98. The decrease in mean and longest apnoea duration was 5.44 ± 14.48 and 10.50 ± 31.70 s, respectively. The decrease in mean and longest hypopnoea duration was 0.89 ± 9.80 and 2.45 ± 35.33 s, respectively.

Table 3 describes the oxygen saturation levels and hypoxic burden according to responder groups. There was a significant increase in mean $O_2$ levels for both responder $\text{MinO}_2\text{only}$ and responder $\text{Congruous}$, while the level decreased in responder $\text{AHI}_{\text{only}}$ following treatment. On the other hand, mean $O_2$ in NREM only did not show a significant change after treatment in responder $\text{MinO}_2\text{only}$. The pre-treatment mean $O_2$ in REM was lowest in responder $\text{MinO}_2\text{only}$. There was a significant difference among groups in pre-treatment min $O_2$ with responder $\text{MinO}_2\text{only}$ showing the lowest values. The difference in min $O_2$ levels were no longer significant post-treatment. The min $O_2$ decreased and $T_{95}$ increased only in the responder $\text{AHI}_{\text{only}}$. There were significantly more patients in the low min $O_2$ (<85%) group in the responder $\text{MinO}_2\text{only}$ pre-treatment.

Although there was a decrease in oxygen saturation in responder $\text{AHI}_{\text{only}}$, there was a significant decrease in ODI post-treatment in this group. The ODI values decreased in the other 2 groups but the difference was not statistically significant.

There was a significant difference in mean and longest apnoea duration pre- and post-treatment among responder groups with responder $\text{AHI}_{\text{only}}$ showing the shortest duration for both values at both measurements. There was a significant decrease in both values post-treatment only in the responder $\text{Congruous}$. The mean hypopnoea duration decreased only in the responder $\text{AHI}_{\text{only}}$, while this value increased in the other 2 responder groups. Although there were no significant differences pre-treatment, the longest hypopnoea duration was significantly higher in the responder $\text{MinO}_2\text{only}$ post-treatment. The longest hypopnoea duration significantly decreased only in the responder $\text{AHI}_{\text{only}}$.

### 3.4 Polysomnographic characteristics of different responder groups’ respiratory parameters

The average amount of reduction in AHI for the total sample was 18.51 ± 14.61 (63.97 ± 27.70% change). Table 4 describes the differences in respiratory parameters between responder groups. In the responder $\text{MinO}_2\text{only}$ group, AHI was reduced only 20.43 ± 31.77%, although the decrease in AHI post-treatment was significant in all 3 groups.

There was a significant difference in the pre-treatment REM AHI among the responder groups with the responder $\text{Congruous}$ showing the highest value and the difference evident between responder $\text{MinO}_2\text{only}$ and responder $\text{Congruous}$. The pre-treatment AI and REM AI values were also significantly different among responder groups; however, this difference did not persist following treatment. Such a significant difference among responder groups did not exist for pre-treatment NREM AI.

There was a significant difference among the responder groups in post-treatment HI and NREM HI values although the difference was not significant pre-treatment. Responder $\text{MinO}_2\text{only}$ showed the highest value that significantly differed from the other two responder groups. The differences for post-treatment HI and NREM HI were evident between responder $\text{MinO}_2\text{only}$ and other groups. There was a significant difference in post-treatment supine and non-supine AHI among the groups although there was no difference pre-treatment.
Correlation between pre-treatment variables and amount of change in oxygen saturation and hypoxic burden levels

A higher pre-treatment AHl showed a significant correlation with a smaller amount of change in \( T_{90} \) (\( r = -0.323 \)) and ODI (\( r = -0.714 \)) with treatment. A higher pre-treatment mean \( O_2 \) (\( r = -0.342 \)) and mean \( O_2 \) in REM (\( r = -0.445 \)) showed a significant correlation with a smaller amount of change in min \( O_2 \) with treatment. A higher pre-treatment min \( O_2 \) and min \( O_2 \) in NREM and REM showed a significant correlation with a smaller amount of change in mean (\( r = -0.486; r = -0.406 \); \( r = -0.479 \), respectively) and min \( O_2 \) (\( r = -0.764; r = -0.651; r = -0.744 \), respectively) and greater change in \( T_{90} \) (\( r = 0.510; r = 0.467; r = 0.471 \), respectively) with treatment. A higher pre-treatment ODI showed a significant correlation with a smaller amount of change in ODI with treatment (\( r = -0.872 \)). A higher pre-treatment mean apnoea (\( r = -0.423 \)) and hypopnoea (\( r = -0.316 \)) duration showed a significant correlation with a smaller amount of change in apnoea-hypopnoea duration with treatment (data not shown).

Pre-treatment variables predicting post-treatment oxygen saturation and hypoxic burden levels

Multiple linear regression analysis results with post-treatment oxygen saturation and hypoxic burden indices as dependent variables are shown in Table S5. Pre-treatment \( O_2 \) and \( T_{90} \) were independent factors negatively associated with post-treatment mean \( O_2 \) levels. Pre-treatment BMI, amount of REM sleep, mean \( O_2 \) and mean apnoea duration were independent factors showing a significant correlation with post-treatment min \( O_2 \) levels. Pre-treatment AHl and min \( O_2 \) were positively associated, while BMI, respiratory arousal index and ODI were negatively associated with post-treatment \( T_{90} \).
TABLE 2 Correlation coefficients based on linear regression analysis of change in oxygen saturation and hypoxic burden parameters following oral appliance treatment

| Variables (per 1 unit change of AHI) | ResponderAHIonly (N = 26) | ResponderMinO2only (N = 9) | ResponderCongruous (N = 13) | Total (N = 48) |
|-------------------------------------|--------------------------|---------------------------|-----------------------------|----------------|
| Mean O₂ saturation (%)             | .059                     | .810**                    | .278                        | .108           |
| Min O₂ saturation (%)              | .098                     | .611                      | .249                        | .090           |
| T90 (%TST)                         | .058                     | .803**                    | .701**                      | .186           |
| ODI (events/h)                     | .640*                    | .797                      | .935**                      | .710**         |
| Mean apnoea duration (s)           | .045                     | .180                      | .239                        | .008           |
| Longest apnoea duration (s)        | .109                     | .016                      | .092                        | .122           |
| Mean hypopnoea duration (s)        | .016                     | .309                      | .586*                       | .130           |
| Longest hypopnoea duration (s)     | .006                     | .008                      | .627*                       | .003           |

Abbreviations: AHI, apnoea-hypopnoea index; Min O₂, minimum oxygen saturation level; ODI, oxygen desaturation index; T90, percentage of time spent oxygen saturation <90%; TST, total sleep time.
*Significant difference: p < .01.
**Significant difference: p < .001.

3.7 Effectiveness of pre-treatment polysomnographic variables to predict the treatment outcome of being a minimum oxygen saturation responder

As shown in Figure 1, there were 5 baseline PSG characteristics, which showed statistically significant chances to predict patients being in the responderMinO2only group. As the receiver operating characteristic (ROC) curve analysis shows, pre-treatment min O₂ level with a cut-off value of 86.25% leads to a AUC of 0.925 (sensitivity 77.27% [95% confidence interval [CI]: 54.63–92.18], specificity 92.31% [95% CI: 74.87–99.05], positive predictive value (PPV) 89.47% [95% CI: 68.77–97.04], negative predictive value (NPV) 82.76% [95% CI: 68.79–91.27]), T90 higher than 1.25% leads to an AUC of 0.761 (sensitivity 68.18% [95% CI: 45.13–86.14], specificity 80.77% [95% CI: 60.65–93.45], PPV 75.00% [95% CI: 56.48–87.40], NPV 75.00% [95% CI: 61.27–85.05]), longest apnoea duration with a 44.2 second cut-off value leads to an AUC of 0.742 (sensitivity of 59.09% [95% CI: 36.35–79.29], specificity 96.15% [95% CI: 80.36–99.90], PPV 92.86% [95% CI: 64.84–98.92], NPV 73.53% [95% CI: 62.56–82.20]) and mean apnoea-hypopnoea duration with a 47.45 second cut-off value leads to an AUC of 0.706 (sensitivity of 68.18% [95% CI: 45.13–86.14], specificity 73.08% [95% CI: 52.21–88.43], PPV 68.18% [95% CI: 51.69–81.10], NPV 73.08% [95% CI: 58.51–83.93]).

All showed higher than acceptable discrimination ability with relatively high sensitivity and specificity to predict those who would show a ≥4% increase in min O₂ following treatment. Pre-treatment AHI was not effective (AUC: 0.613) in doing so.

4 DISCUSSION

This is the first study to define groups according to disparity in the improvement of AHI and min O₂ saturation levels following OA treatment for OSA and quantitatively analyse the change in oxygenation and hypoxic burden levels in relation to respiratory indices. The results showed that 35% of OSA patients treated with an OA do not show a significant decrease in AHI nor a notable increase in oxygen saturation levels. Furthermore, 47% showed a discrepancy between the improvement of AHI and oxygen saturation levels with OA treatment, as 35% showed only a significant improvement in the AHI and 12% only improvements in the oxygen saturation levels. Such results are the first to quantitatively show the mismatch in the treatment response rate based on the two most commonly applied indices in measuring OSA treatment outcomes. In spite of the betterment of airflow through OA treatment, many patients did not experience a significant improvement in their oxygenation levels and the rate of treatment success may vary according to the criteria that was implemented.

Although AHI has been widely accepted as a standard to diagnose and evaluate OSA, long-term adverse health outcomes are not only related to airflow and arousals but also hypoxaemia. Studies show that min O₂ is a better prognostic factor in the evaluation of cardiovascular comorbidities. AHI alone often shows only weak correlation with OSA related complications and plays a stronger role in the progress of cardiovascular problems when combined with nocturnal hypoxaemia. However, treatment success for OSA has been traditionally defined solely on the basis of AHI. The results of this study showed that the improvement in min O₂ level was less than 4% in 35% of the OSA patients treated with OA who would have been considered successfully treated based on the >50% AHI reduction criterion. Applying AHI as the sole criteria for the decision of OA titration could lead to deleterious long-term health outcomes especially those related to cardiovascular damage due to intermittent hypoxaemia. This is in line with a previous study showing that the min O₂ of severe OSA patients remained below 90% even with OA treatment, suggesting the need to evaluate treatment success based on oxygen saturation levels. Min O₂ rather than mean O₂ was used as a grouping criteria in this investigation based on studies showing its close relationship with general health outcomes such...
as cognition and cardiovascular disease. Based on a recent review, OA reduces ODI by 9.6 events per hour on average, and the amount of improvement in oxygenation levels was estimated as an improvement of mean and minimum oxygen saturation levels of 2.9% and 3.7%, respectively. Such values are in line with those from our study which shows an average increase in min O$_2$ of 4.2% and decrease in ODI of 9.58 ± 2.9% and 3.7%, respectively. 27 Such values are in line with those from other studies on OA treatment. However, in the present study, the increase in mean O$_2$ level was 0.12 ± 1.73%, which is lower compared to the estimate from other studies on OA treatment. This may be due to the fact that patients of this study were of a relatively higher severity (AHI: 28.55 ± 18.86) while most studies on OA treatment are based on mild to moderate OSA patients. The improvement level in T90 has rarely been reported with OA therapy. Results with CPAP showed approximately a 2.6% decrease in T90, which is higher than the 1.36 ± 6.03% reduction achieved with our patients after OA therapy.32

The disparity observed in the improvement of AHI and min O$_2$ in the patients of our study could be partially explained by the difference in baseline oxygenation levels. Min O$_2$ level was significantly lower for the responder group before treatment; however,

### TABLE 3 Polysomnographic characteristics according to responder group-oxygen saturation and hypoxic burden

| Variables                        | Responder AHIonly ($N = 26$) | Responder MinO2only ($N = 9$) | Responder Congruous ($N = 13$) |
|----------------------------------|-------------------------------|-------------------------------|---------------------------------|
|                                  | Pre-OA                        | Post-OA                       | Pre-OA                          | Post-OA                        | Pre-OA                          | Post-OA                        |
| Mean O$_2$ saturation (%)$^a$    | 95.47 (1.85)**                | 94.66 (2.80)**                | 93.99 (3.04)**                  | 95.12 (2.21)**                 | 94.99 (1.52)**                  | 96.28 (1.66)**                 |
| NREM mean O$_2$                 | 95.28 (1.98)**                | 94.62 (2.57)**                | 95.04 (1.69)                    | 95.51 (1.81)                    | 95.32 (1.43)**                  | 96.21 (1.51)**                 |
| REM mean O$_2$                  | 95.65 (1.79)**                | 94.70 (3.11)**                | 92.93 (4.74)**                  | 94.73 (3.17)**                  | 94.67 (1.85)**                  | 96.35 (1.90)**                 |
| Min O$_2$ saturation (%)$^b$      | 90.10 (2.94)*                 | 89.52 (5.14)                  | 77.19 (13.12)**                 | 86.56 (8.45)**                  | 80.55 (7.00)**                  | 90.77 (4.07)**                 |
| NREM min O$_2$                  | 89.35 (3.56)*                 | 88.50 (6.14)                  | 76.40 (13.11)**                 | 88.11 (5.21)**                  | 83.56 (6.22)**                  | 91.23 (3.14)**                 |
| REM min O$_2$                   | 90.83 (3.58)*                 | 90.54 (5.16)                  | 78.00 (14.63)**                 | 85.00 (12.00)**                 | 77.53 (10.66)**                 | 90.31 (5.17)**                 |
| T$_{90}$ (%TST)$^a$             | 3.81 (14.46)                  | 4.80 (18.93)                  | 7.40 (10.08)**                  | 2.68 (5.35)**                   | 4.39 (5.66)**                   | 0.64 (1.65)**                  |
| Mean O$_2$ group$^b$            | 13/13                         | 9/17                          | 3/6**                          | 4/5**                          | 4/9                            | 8/5                            |
| Min O$_2$ group$^b$             | 25/1*                         | 22/4                          | 3/6*                           | 7/2                            | 5/8*                           | 12/1                           |
| ODI$^a$                         | 17.03 (12.86)**               | 5.98 (4.61)**                 | 22.78 (24.82)                  | 14.13 (13.61)                  | 16.83 (14.41)                  | 6.23 (5.91) ($n = 7$)          |
| ODI severity$^a$ (normal/mild/moderate/severe) | 3/3/4/3**                  | 7/10/0/0**                    | 1/1/2/1                        | 1/4/0/1                        | 2/1/2/1                        | 4/2/1/0                        |
| Mean apnoea duration (s)$^a$     | 17.15 (13.78, 22.10)          | 13.80 (0.00, 18.43)           | 25.70 (16.80, 29.10)            | 23.80 (9.00, 29.90)             | 28.30** (16.30, 34.35)          | 18.90** (6.15, 27.75)           |
| Longest apnoea duration$^a$      | 23.13 (15.13)*                | 15.32 (17.99)*                | 51.93 (37.79)*                  | 54.07 (45.62)*                  | 49.44 (29.85)**                 | 24.82 (21.51)**                |
| Mean hypopnoea duration$^a$      | 24.12 (6.80)                  | 23.72 (9.38)                  | 25.74 (4.97)                    | 29.07 (8.55)                    | 25.22 (6.31)                    | 26.99 (6.27)                    |
| Longest hypopnoea duration$^a$    | 58.58 (21.13)**               | 45.75 (22.49)**               | 64.31 (16.18)                   | 91.79 (37.44)*                  | 58.49 (20.25)                   | 56.09 (23.54)*                  |
| A-H duration group$^h,d$ (1/2/3/4) | 1/5/9/11                     | 2/8/8/8                      | 0/0/2/7                        | 0/1/2/6                        | 1/0/2/8                        | 1/1/3/8                        |
| Change in mean O$_2$$^a$           | −0.81 (1.59)*                 | 1.13 (1.15)*                  | 1.28 (1.24)*                    |                               |                               |                               |
| Change in min O$_2$$^a$            | −0.57 (4.64)*                 | 9.36 (5.78)*                  | 10.22 (4.42)*                   |                               |                               |                               |
| Change in T$_{90}$$^a$         | 1.00 (5.40)                   | −4.72 (6.19)*                 | −3.75 (5.40)*                   |                               |                               |                               |
| Change in ODI$^f$                | −8.40 (−16.18, −1.07)         | −5.95 (−20.38, 9.83)          | −10.30 (−15.10, −0.57)          |                               |                               |                               |

Abbreviations: A-H, apnoea-hypopnoea; AHI, apnoea-hypopnoea index; Min O$_2$, minimum oxygen saturation level; NREM, non-rapid eye movement; OA, oral appliance; ODI, oxygen desaturation index; REM, rapid eye movement; T$_{90}$, percentage of time spent oxygen saturation <90%; TST, total sleep time.

$^a$Significant difference: $p < .05$, comparison among responder groups.

$^b$Significant difference: $p < .05$, comparison between pre- and post-oral appliance treatment.

$^c$Differences among groups were tested with one-way ANOVA test and pre- and post-OA data within groups were tested with paired t-test: Mean (SD).

$^d$Differences among groups and pre- and post-OA data were tested with Chi-square test.

$^e$Differences among groups were tested with Kruskal–Wallis one-way ANOVA test and pre- and post-OA data were tested with Wilcoxon Rank-sum test: Median (lower quartile, upper quartile).

$^f$1: 10 to <20 s; 2: 20 to <30 s; 3: 30 to <40 s; 4: >40 s.
such significance was lost following OA therapy and the min O2 level was similar in all 3 responder groups post-treatment at a level converging to approximately 90%. Those with a very low min O2 level pre-treatment may show the largest amount of improvement in hypoxaemia levels, while those with a relatively higher min O2 level pre-treatment will show minimal improvement in spite of the decrease in AHI. Such incongruity between the two indices can also be seen in the correlation coefficients from regression analysis showing a lack of significance in the amount of change in Min O2 in relation to 1-unit change of AHI. One could speculate based on the higher efficacy of CPAP compared to OA in correcting hypoxaemia that there would be less patients that show a minimal amount of improvement in oxygenation levels when the AHI value is sufficiently rectified. Studies based on CPAP showed a 9%–22% increase in min O2 post-treatment. A low baseline min O2 should not be a contra-indication of OA treatment as we found that patients with an average min O2 of <86% tend to show a greater response to OA treatment.

### TABLE 4 Polysomnographic characteristics according to responder group—respiratory parameters

| Variables                  | Responder_{AHIonly} (N = 26) | Responder_{MinO2only} (N = 9) | Responder_{Congruous} (N = 13) |
|----------------------------|-------------------------------|-------------------------------|---------------------------------|
|                            | Pre-OA | Post-OA | Pre-OA | Post-OA | Pre-OA | Post-OA |
| AHI¹                      | 26.11 (19.97)** | 6.56 (7.62)** | 30.09 (18.64)** | 21.97 (11.58)** | 32.36 (17.34)** | 8.75 (5.29)** |
| REM AHI¹                  | 26.55 (23.12)** | 9.19 (13.39)** | 33.02 (16.10)* | 30.60 (12.39)* | 45.26 (13.60)** | 17.15 (13.81)** |
| NREM AHI¹                 | 25.08 (19.77)** | 5.84 (8.86)** | 26.88 (20.85) | 19.44 (12.97)* | 29.17 (19.74)** | 7.00 (5.55)** |
| AI¹                       | 2.98 (3.91)* | 1.50 (4.96) | 12.82 (18.57)* | 4.83 (5.52) | 9.75 (14.03)** | 1.84 (2.56)** |
| REM AI¹                   | 3.01 (6.37)* | 1.26 (3.37)* | 16.19 (15.82)* | 12.70 (13.04)* | 21.61 (20.71)** | 4.86 (8.69)** |
| NREM AI¹                  | 0.75** (0.00, 4.60) | 0.00** (0.00, 0.85) | 2.00 (0.20, 18.40) | 0.40 (0.20, 4.65) | 3.00** (0.20, 19.60) | 0.60** (0.00, 1.90) |
| HI¹                       | 22.44 (18.55)** | 4.82 (3.49)** | 15.78 (4.80) | 16.79 (8.68)* | 17.51 (12.80)** | 6.60 (4.17)** |
| REM HI¹                   | 23.55 (21.49)** | 7.92 (13.04)** | 16.83 (13.86) | 17.90 (10.83) | 23.65 (17.34) | 12.29 (11.43) |
| NREM HI¹                  | 22.12 (18.96)** | 4.26 (4.08)** | 15.39 (5.34) | 16.37 (9.77)* | 16.18 (12.76)** | 5.48 (4.26)** |
| CI¹                       | 0.69 (1.54) | 0.24 (0.47) | 1.49 (2.62) | 0.34 (0.89) | 0.15 (0.36) | 0.31 (0.82) |
| OSA severity²             | 1/6/12/7** | 11/14/0/1,* | 0/0/7/2** | 0/3/4/2,** | 0/3/4/6 | 5/7/1/0* |
| (normal/mild/moderate/severe) |                     |                        |                        |                     |                        |                |
| Supine AHI¹               | 38.92 (33.37)** | 10.29 (18.04)** | 43.14 (27.72) | 27.47 (11.84)* | 36.85 (22.06)** | 14.74 (17.49)** |
| Non-supine AHI¹           | 19.55 (23.76)** | 5.11 (6.10)** | 14.18 (11.43) | 17.14 (14.48)* | 15.56 (15.13)** | 4.87 (3.73)** |
| Supine time (h)¹          | 2.08 (1.80) | 1.59 (1.50) | 3.00 (2.44) | 3.00 (1.09) | 2.67 (2.33) | 2.48 (2.15) |
| Positional OSA³           | 12/14 | 11/15 | 5/4 | 3/6 | 8/5 | 7/6 |
| (positional/non)            |                     |                        |                        |                     |                        |                |
| REM-related OSA³          | 7/19 | 11/15 | 3/6 | 4/5 | 6/7 | 8/5 |
| (related/not)               |                     |                        |                        |                     |                        |                |
| HAR³                      | 6.67 (2.83, 23.67) | 4.13 (1.24, 10.61) | 2.44** (0.73, 9.02) | 3.25** (1.80, 4.51) | 2.45 (0.37, 17.58) | 3.61 (1.82, 13.58) |
| Event type dominance⁴      | 1/24/1* | 0/21/5 | 1/5/3* | 0/7/2 | 3/7/3* | 0/11/2 |
| (apnea/hypopnea/neither)   |                     |                        |                        |                     |                        |                |
| Change in AHI (%)⁴         | 75.24 (13.19)* | 20.43 (31.77)* | 20.43 (31.77)* | 71.56 (14.55)* |

Abbreviations: AHI, apnoea-hypopnoea index; AI, apnoea index; CI, central index; HAR, hypopnoea/apnoea ratio; HI, hypopnoea index; Min O2, minimum oxygen saturation level; NREM, non-rapid eye movement; OA, oral appliance; OSA, obstructive sleep apnoea; REM, rapid eye movement.

*Significant difference: p < .05, comparison among responder groups.

**Significant difference: p < .05, comparison between pre- and post-oral appliance treatment.

Differences among groups were tested with one-way ANOVA test and pre- and post-OA data within groups were tested with paired t-test: Mean (SD).

Differences among groups were tested with Kruskal–Wallis one-way ANOVA test and pre- and post-OA data were tested with Wilcoxon Rank-sum test: Median (lower quartile, upper quartile).

Differences among groups were tested with Chi-square test and pre- and post-OA data were tested with McNemar's and chi-square test.

²Apnoea-predominant: HAR ≤ 0.5; hypopnoea-predominant: HAR > 2; neither: 0.5 < HAR ≤ 2.
Pre-treatment mean O₂ showed a significant difference among responder groups only in REM sleep and the amount of time spent in REM sleep pre-treatment was significantly related to post-treatment min O₂ levels. This could implicate a sleep stage dependency in treatment response. It is well known that OSA worsens during REM sleep and REM OSA may act as an independent risk factor for adverse health outcomes.

ROC curve analysis showed that pre-treatment min O₂ level showed the strongest ability to predict those who would show a ≥4% increase in min O₂ following OA treatment, while pre-treatment AHI was not effective. Pre-treatment min O₂ ≤86.25% could be considered in patient selection and setting treatment goals as such patients are likely to show a ≥4% increase in min O₂ following treatment.

The respiratory events were differently constituted as responderMinO₂only had an increased HAR after treatment where the responderAHIonly group showed a decrease in this ratio. The marked elimination of apnoeas may have led to the significant increase in min O₂ levels in the responderMinO₂only group. OA treatment is known to convert apnoeas into hypopnoeas with the HAR increasing along with the decrease in overall AHI.

Correlation analysis results have shown that pre-treatment min O₂ levels were most significantly related to the amount of change in oxygen saturation levels including not only mean and min O₂ levels but also T₉₀ along with multiple regression analysis results showing min O₂ as a significant predictor of post-treatment mean O₂ and T₉₀. All results direct towards a trend of lower pre-treatment min O₂ resulting in a significantly more positive improvement in oxygenation status post-treatment. This result should be considered in conjunction with the fact that there may be a ceiling effect in the improvement of min O₂ level achievable with OA treatment for OSA. Interestingly, for non-responders mean apnoea duration was a significant predictor of post-treatment mean O₂ (β = −0.468, p = .018), min O₂ (β = −0.428, p = .029), and T₉₀ (β = 0.422, p = .001).

There are limitations of this study due to its retrospective design that limit the general application of the predictive variables and cut-off values in patient populations of different characteristics. Studied variables and cut-off values should be tested in diverse patient populations.

### TABLE 5 Multiple regression of pre-treatment variables predicting post-treatment oxygen saturation and hypoxic burden levels

| Predictor variable         | Mean O₂  | Min O₂  | T₉₀   |
|----------------------------|----------|---------|-------|
| BMI                        | 0.011    | 0.475*  | −0.147*|
| AHI                        | −0.463   | 0.426   | 0.577**|
| HAR                        | 0.155    | 0.033   | −0.042|
| REM sleep                  | 0.056    | 0.659** | −0.096|
| Respiratory arousal index  | 0.334    | −0.783  | −0.408**|
| Mean O₂                    | −        | 1.425** | −0.212|
| Min O₂                     | −0.767*  | −       | 0.371**|
| T₉₀                        | −0.652** | 0.106   | −     |
| ODI                        | −0.043   | 0.147   | −0.337**|
| Mean apnoea duration       | −0.197   | −0.690**| 0.051|
| Mean hypopnoea duration    | −0.055   | 0.035   | −0.016|

Note: All regression coefficients are standardized.

Abbreviations: AHI, apnoea-hypopnoea index; BMI, body mass index; HAR, hypopnoea/apnoea ratio; Min O₂, minimum oxygen saturation; ODI, oxygen desaturation index; REM, rapid eye movement; T₉₀, percentage of time spent oxygen saturation <90%.

Significant difference: *p < .05; **p < .01.
populations to verify its reliability in future studies. However, the usage of level 1 PSG conducted pre- and post-treatment in the same facility with regular concordance activities and the standardised OA treatment protocol identically applied to all patients of this study assigns reliability to the derived results. Also, the relatively small sample size of subgroups warrants further studies with larger subject numbers. Another point to consider is the oxygen related index to apply in treatment evaluation. Focussing on changes in nadir oxygen saturation level itself may be more intuitive to interpret and is important as it focuses on the individual baseline improvement and the amount of time that the mean oxygen level remains low, rather than discussing the presence of a change in min O$_2$ level of ≥4% or 3%.

The results of this study that defined groups based on both responses in AHI and min O$_2$ saturation levels following OA treatment for OSA show that certain patients do not show a sufficient decrease in hypoxaemia in spite of the improvement in AHI and subgroups exist within OA treatment responders with distinct post-treatment characteristics of AHI and oxygen saturation levels. Such results suggest that the evaluation of treatment response based on AHI as the only criteria could hinder accurate measurement of treatment success and long-term prognosis.

5 | CONCLUSIONS

Pre-treatment min O$_2$ levels should be considered in OA treatment titration regarding its close relation to improvements in oxygenation levels with OA treatment and systemic sequelae. Patients with increased desaturation should not be excluded from OA therapy, as in the present study, these patients have shown an important and more significant increase in oxygen levels compared to patients who did not present low levels of oxygenation at baseline.

ACKNOWLEDGEMENTS

We thank, Mary Wong, Faculty of Dentistry, University of British Columbia for her support with data management and statistical analysis.

CONFLICT OF INTEREST

The authors report no conflicts of interest that may have affected the work.

AUTHOR CONTRIBUTIONS

Ji Woon Park participated in data analysis and interpretation of data, and also in drafting and revising the manuscript critically for important intellectual content. Fernanda R. Almeida initiated the study project and participated in the acquisition of data, data analysis and interpretation of data, and also in drafting and revising the manuscript critically for important intellectual content. All authors reviewed and revised the manuscript, and approved the final version of the manuscript.

REFERENCES

1. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177:1006-1014.
2. Kapur VK, Alfonso-Cristancho R. Just a good deal or truly a steal? Medical cost savings and the impact on the cost-effectiveness of treating sleep apnea. Sleep. 2009;32:135-136.
3. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014;383:736-747.
4. Montserrat J, Ferrer M, Hernandez L, et al. Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome: a randomized controlled study with an optimized placebo. Am J Resp Crit Care Med. 2001;164:608-613.
5. Marco Pitarch R, Selva Garcia M, Puertas Cuesta J, Marco Algarra J, Fernández Julian E, Fons FA. Effectiveness of a mandibular advancement device in obstructive sleep apnea patients: a prospective clinical trial. Eur Arch Otorhinolaryngol. 2018;275:1903-1911.
6. Kartali N, Daskalopoulou E, Geleris P, et al. The effect of continuous positive airway pressure therapy on blood pressure and arterial stiffness in hypertensive patients with obstructive sleep apnea. Sleep Breath. 2014;18:635-640.
7. Libman E, Bailes S, Fichten CS, et al. CPAP treatment adherence in women with obstructive sleep apnea. Sleep Disord. 2017;2017:2760650.
8. McArdle N, Devereux G, Heldarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 1999;159:1108-1114.
9. Ramar K, Dort LC, Katz 5G, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;21:773-827.
10. Gjerde K, Lehmann S, Berge ME, Johansson AK, Johansson A. Oral appliance treatment in moderate and severe obstructive sleep apnoea patients non-adherent to CPAP. J Oral Rehabil. 2016;43:249-258.
11. Serra-Torres S, Bellot-Arcis C, Montiel-Company JM, Marco-Algarra J, Almerich-Silla JM. Effectiveness of mandibular advancement appliances in treating obstructive sleep apnea syndrome: a systematic review. Laryngoscope. 2016;126:507-514.
12. Almendros I, Martinez-Garcia MA, Farré R, Gozal D. Obesity, sleep apnea, and cancer. Int J Obes. 2020;44:1653-1667.
13. Chen L-D, Chen Q, Lin XJ, et al. Effect of chronic intermittent hypoxia on gene expression profiles of rat liver: a better understanding of OSA-related liver disease. Sleep Breath. 2020;24:761-770.
14. Punjabi NM, Newman AB, Young TB, Resnick HE, Sanders MH. Sleep-disordered breathing and cardiovascular disease: an outcome-based definition of hypopneas. Am J Respir Crit Care Med. 2008;177:1150-1155.
15. Weaver EM, Woodson BT, Steward DL. Polysomnography indexes are discordant with quality of life, symptoms, and
reaction times in sleep apnea patients. Otolaryngol Head Neck Surg. 2005;132:255-262.

16. Brown DL, Shafie-Khorassani F, Kim S, et al. Do apneas and hypopneas best reflect risk for poor outcomes after stroke? Sleep Med. 2019;63:14-17.

17. Natsios G, Pastaka C, Vavougios G, et al. Age, body mass index, and daytime and nocturnal hypoxia as predictors of hypertension in patients with obstructive sleep apnea. J Clin Hypertens. 2016;18:146-152.

18. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012;8(5):597-619.

19. Oksenberg A, Silverberg DS, Arons E, Radwan H. Positional vs nonpositional obstructive sleep apnea patients: anthropomorphic, nocturnal polysomnographic, and multiple sleep latency test data. Chest. 1997;112:629-639.

20. Koo BB, Patel SR, Strohl K, Hoffstein V. Rapid eye movement-related sleep-disordered breathing: influence of age and gender. Chest. 2008;134:1156-1161.

21. Mathew R, Castriotta RJ. High hypopnea/apnea ratio (HAR) in extreme obesity. J Clin Sleep Med. 2014;10:391-396.

22. Sutherland K, Takaya H, Qian J, Petocz P, Ng AT, Cistulli PA. Oral appliance treatment response and polysomnographic phenotypes of obstructive sleep apnea. J Clin Sleep Med. 2015;11:861-868.

23. Kulkas A, Duce B, Leppänen T, Hukins C, Töyräs J. Severity of desaturation events differs between hypopnea and obstructive apnea events and is modulated by their duration in obstructive sleep apnea. Sleep Breath. 2017;21:829-835.

24. Xie J, Sert Kuniyoshi FH, Covassin N, et al. Nocturnal hypoxemia due to obstructive sleep apnea is an independent predictor of poor prognosis after myocardial infarction. J Am Heart Assoc. 2016;5:e003162.

25. Vold ML, Aasebøe U, Wilsgaard T, Melbye H. Low oxygen saturation and mortality in an adult cohort: the Tromsø study. BMC Pulm Med. 2015;15:9.

26. Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls [Internet]. StatPearls Publishing; 2020.

27. Sutherland K, Vanderveken OM, Tsuda H, et al. Oral appliance treatment for obstructive sleep apnea: an update. J Clin Sleep Med. 2014;10:215-227.

28. Almeida FR, Lowe AA, Tsuiki S, et al. Long-term compliance and side effects of oral appliances used for the treatment of snoring and obstructive sleep apnea syndrome. J Clin Sleep Med. 2005;1:143-152.

29. Fukuda T, Tsuiki S, Kobayashi M, Nakayama H, Inoue Y. Selection of response criteria affects the success rate of oral appliance treatment for obstructive sleep apnea. Sleep Med. 2014;15:367-370.

30. Kato K, Noda A, Yasuma F, et al. Effects of sleep-disordered breathing and hypertension on cognitive function in elderly adults. Clin Exp Hypertens. 2020;42:250-256.

31. Gunnarsson SI, Peppard PE, Korcarz CE, et al. Minimal nocturnal oxygen saturation predicts future subclinical carotid atherosclerosis: the Wisconsin sleep cohort. J Sleep Res. 2015;24:680-686.

32. Gottlieb DJ, Punjabi NM, Mehra R, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014;370:2276-2285.

33. White J, Cates C, Wright J. Continuous positive airways pressure for obstructive sleep apnoea. Cochrane Database Syst Rev. 2002(2):CD001106.

34. Liu T, Li W, Zhou H, Wang Z. Verifying the relative efficacy between continuous positive airway pressure therapy and its alternatives for obstructive sleep apnea: a network meta-analysis. Front Neurol. 2017;8:289.

35. Wang X-T, Zhao G, Tu L, et al. Continuous positive airway pressure effectively alleviates arrhythmias in patients with obstructive sleep apnea: possible relationship with counteracting oxidative stress. Curr Med Sci. 2019;39:52-58.

36. Varga AW, Mokhlesi B. REM obstructive sleep apnea: risk for adverse health outcomes and novel treatments. Sleep Breath. 2019;23:413-423.